These efforts may ultimately facilitate the development of clinically actionable prognostic tools that integrate molecular markers, such as TOP2A, into conventional staging systems, thereby advancing personalized treatment approaches for patients with SCCE. This evidence concerns the gene TOP2A and cervical small cell carcinoma.